Doors Close And Open For Oramed In China Diabetes Market
This article was originally published in PharmAsia News
Executive Summary
An intended licensing agreement between Wuzhou Zhongheng Group and Oramed for diabetes drugs may have fallen apart, but Zhongheng will continue to acquire new products abroad as part of its development strategy, while Oramed has tied up with another partner in the large and growing Chinese diabetes market, which has already attracted many multinationals.